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The Epigenetic Regulator I-BET151 Induces
BIM-Dependent Apoptosis and Cell Cycle Arrest of
Human Melanoma Cells
Stuart J. Gallagher1, Branka Mijatov1, Dilini Gunatilake1, Jessamy C. Tiffen1, Kavitha Gowrishankar1, Lei Jin1,
Gulietta M. Pupo2, Carleen Cullinane3,4, Rab K. Prinjha5, Nicholas Smithers5, Grant A. McArthur3,4,
Helen Rizos2 and Peter Hersey1,6
Epigenetic changes are widespread in melanoma and contribute to the pathogenic biology of this disease. In the
present study, we show that I-BET151, which belongs to a new class of drugs that target the BET family of
epigenetic ‘‘reader’’ proteins, inhibits melanoma growth in vivo and induced variable degrees of apoptosis in a
panel of melanoma cells. Apoptosis was caspase dependent and associated with G1 cell cycle arrest. All
melanoma cells tested had increased levels of the BH3 proapoptotic protein BIM, which appeared to be regulated
by the BRD2 BET protein and to some extent by BRD3. In contrast, knockdown experiments indicated that
inhibition of BRD4 was associated with decreased levels of BIM. Apoptosis was dependent on BIM in some but
not all cell lines, indicating that other factors were determinants of apoptosis, such as downregulation of
antiapoptotic proteins revealed in gene expression arrays. G1 cell cycle arrest appeared to be mediated by p21
and resulted from inhibition of the BRD4 protein. The activity of BET protein inhibitors appears independent of
the BRAF and NRAS mutational status of melanoma, and further studies to assess their therapeutic role in
melanoma are warranted.
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INTRODUCTION
Although there have been major advances in the treatment of
melanoma based on the use of targeted therapies (Jang and
Atkins, 2013; Sullivan et al., 2013) and immunotherapy with
monoclonal antibodies against checkpoint inhibitors (Riley,
2013; Robert et al., 2013), the disease remains incurable in
the majority of patients. We have reviewed elsewhere some of
the evidence that epigenetic changes underlie many aspects of
melanoma biology (Lai et al., 2012b), including resistance to
targeted therapies, melanoma invasiveness (Saladi et al.,
2010), and regulation of microphthalmia-associated
transcription factor (Keenen et al., 2010). These and studies
by others indicate that dysregulation of chromatin is a frequent
event in melanoma (Becker et al., 2009; Hodis et al., 2012;
van den Hurk et al., 2012) and other cancers (Fullgrabe et al.,
2011; Blair and Yan, 2012; Dawson and Kouzarides, 2012);
yet, the role of new therapies targeting the epigenetic changes
in melanoma remains under explored.
Chromatin regulation is largely due to the methylation
of DNA or due to modification of histones. Histones are
modified by several protein groups that act either as ‘‘writers’’
by adding acetyl, methyl, or other groups to histones or as
‘‘erasers’’ that remove such groups and included histone
deacetylases (HDACs) and demethylases. The writers and
erasers establish what is referred to as a ‘‘histone code’’ that
is ‘‘read’’ by a third family of proteins that recognize the
histone code and act to focus large protein complexes to those
sites (Arrowsmith et al., 2012; Dawson et al., 2012). These
protein complexes or modules appear characteristic of the
gene expression status, such as repression or activation, and
the particular tissues involved (Ram et al., 2011; Ernst and
Kellis, 2012). For example, mapping of just nine acetyl and
methyl marks was found to define 15 chromatin states relating
to transcriptional activity of surrounding genes (Arrowsmith
et al., 2012).
Particular interest has focused on the development of
inhibitors against a highly conserved class of ‘‘reader’’
proteins, referred to as bromodomain and extraterminal (BET)
proteins. The BET family, which consists of BRD2, BRD3,
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BRD4, and the testis-specific BRDT, has two bromodomains in
the N-terminal region that bind to acetylated lysines in histones
and a C-terminal region that binds to transcription elongation
factors (Filippakopoulos et al., 2012). The bromodomains act
to target protein complexes to particular chromosomal regions
involved in gene transcription, and act as coregulators of
transcription (Belkina and Denis, 2012; Prinjha et al., 2012).
The first BET inhibitor JQ1 inhibited the growth of rare
NUT (nuclear protein of testis) midline carcinomas that are
caused by fusion of the BRD4 BET protein with theNUT
(Filippakopoulos et al., 2010). Related BET protein inhibitors
I-BET151 and I-BET762 have been described by Nicodeme
et al. (2010) (Nicodeme et al., 2010) and shown to inhibit BET
proteins BRD2, BRD3, and BRD4. Subsequent studies have
shown that BRD4 appears to be the target of these drugs in
AML (Zuber et al., 2011), neuroblastoma (Puissant et al.,
2013a), and melanoma (Segura et al., 2013b). The effects on
AML and of other c-Myc-dependent tumors were believed to
be largely due to the downregulation of c-Myc (Delmore et al.,
2011; Mertz et al., 2011).
We and others have shown that pan-HDAC inhibitors can
induce apoptosis in melanoma that is associated with upre-
gulation of BIM, BAX, and BIK and downregulation of Bcl-XL
and XIAP (Zhang et al., 2004; Gillespie et al., 2006; Lai et al.,
2012b). Such inhibitors were also strongly synergistic with
selective BRAF inhibitors in induction of apoptosis of
melanoma (Hersey et al., 2010). In the present study, we
examined the influence of the BET protein inhibitor I-BET151
on the survival of a series of human melanoma cells including
short-term melanoma cultures established from patients who
relapsed while on treatment with the BRAF inhibitor vemu-
rafenib. We report that I-BET 151 induces cell cycle arrest and
apoptosis in melanoma and inhibits melanoma cell survival.
These effects are at least in part due to the inhibition of BET-
mediated suppression of the cyclin-dependent kinase inhibitor
p21 and BET-mediated activation of the proapoptotic BH3-
only protein BIM.
RESULTS
I-BET151 induces melanoma cell death and cell cycle arrest and
inhibits melanoma growth in vivo
To determine the effect of I-BET151 on the growth of
melanoma cells, we examined the sensitivity of Me1007
melanoma cells over a range of drug doses and culture
periods. As shown in Figure 1a, growth inhibition was seen
after 48–72 hours at both 10mM and 100mM of drug, and also
after 24 hours at the higher concentration. In view of this and
pharmokinetic studies showing attainable in vivo blood con-
centrations of at least 10mM for 12 hours following dosing
(Dawson et al., 2011), subsequent studies were carried out at
the lower 10mM I-BET151 concentration after 48 hours
treatment, unless shown otherwise. I-BET151 also inhibited
the growth of other melanoma cell lines to various degrees
(Supplementary Figure S1a).
To assess whether I-BET151 also had activity in vivo, we
tested the effects of I-BET151 in NOD/SCID mice with mela-
noma xenografts. Xenografts were established by injecting
Patient-1-post cells into the flank of NOD/SCID mice, and
after tumors had established the mice were given 25 mg kg 1
I-BET151 or vehicle once daily by oral gavage for 7 days
followed by a 2-day break before treatment was recom-
menced at 20 mg kg1. This schedule was well tolerated with
mean body weight not exceeding 10% (Supplementary Figure
S1b). I-BET151 treatment significantly inhibited Patient-1-post
tumor growth by 56% on day 15 (Po0.001, t-test; Figure 1b).
We then assessed whether I-BET151 could induce apoptosis
or inhibit the cell cycle in a panel of melanoma cell lines.
Little apoptosis was observed after 24 hours of I-BET151
treatment (data not shown); however, apoptosis was observed
in some lines after 48 hours (Figure 1c), suggesting relatively
slow kinetics of apoptosis induction. Of the continuous
melanoma cell lines, the NRAS mutant cell line (Mel-RM)
and the NRAS/BRAF wild-type line (Me1007) were sensitive to
I-BET151, whereas the NRAS mutant/BRAF wild-type (Mel-JD)
and NRAS wild-type/BRAF mutant cell lines (SK-Mel-28, Mel-
RMU) were relatively insensitive to this drug (Figure 1c and
Supplementary Figure S2). Apoptosis was induced at high
levels in the pretreatment lines from patient 3 and less so in
the pretreatment line from patient 1. Both post-relapse lines
from these patients were relatively resistant in apoptosis
assays. Normal neonatal human epidermal melanocytes and
dermal fibroblasts did not undergo cell death with I-BET151
treatment (Figure 1c).
G1 arrest was induced by I-BET151 and was more evident
in the pretreatment primary cultures from patients 1 and 3
than in the corresponding post-relapse lines (Figure 1d
and Supplementary Figure S3). A reduction in cells entering
S-phase and replicating DNA was confirmed using
BrdU/7-AAD dual staining in Patient-1-pre and Patient-3-
pre cells, confirming G1 arrest (supplementary Figure S4A).
Varied levels of G1 arrest were documented in the continuous
cell lines, ranging from a prominent arrest (Mel-RM) to
negligible levels in Mel-RMU. There was relatively little G1
arrest in the sensitive Me1007, although S-phase inhibition
and an increase in G2/M population were observed. A
decrease in S-phase was observed in all cell lines (P-value
o0.05, Welch’s t-test).
I-BET151 upregulates the proapoptotic BH3 protein BIM but not
other BH3 proteins
To investigate the mechanism of I-BET151-induced apoptosis,
we carried out western blots on a range of pro- and
antiapoptotic proteins in five of the melanoma cell lines. As
shown in Figure 2a, after 48 hours of I-BET151 treatment, there
was consistent upregulation of BIM-EL and its isoforms and
downregulation of Puma, Bik, tBID, and BMF to varying
degrees in the different cell lines. SK-Mel-28 had high levels
of BIM in the untreated and treated samples. There were
minimal or variable changes in BAX, BAK, and NOXA.
Among the antiapoptotic proteins, there were consistent
decreases in the XIAP inhibitor of apoptosis protein, small
increases in MCL-1 levels, and small decreases in Bcl-2 and
Bcl-XL. The increases in BIM (particularly the short isoform)
and decreases in the antiapoptotic proteins were most evident
in the two relatively sensitive lines Me1007 and Mel-RM, and
this coincided with PARP cleavage and the presence of
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cleaved caspase 3 (Figure 2a). Similar changes were seen
in the western blots of cell lines from patients 1 and 3
(Supplementary Figure S4B).
Apoptosis was caspase dependent and mediated in part by BIM
We investigated whether apoptosis was caspase dependent by
pretreating cells with the pan-caspase inhibitor Q-VD-OPh
(Kuzelova et al., 2011). As shown in Figure 2b, caspase
inhibition almost completely prevented I-BET151-mediated
apoptosis in the three most sensitive cell lines. Tumor necrosis
factor–related apoptosis-inducing ligand-induced apoptosis
was used as a positive control and is known to be caspase
driven. Previous studies have shown that Me1007 cells
lack caspase 8 and are resistant to tumor necrosis factor–
related apoptosis-inducing ligand (Hersey and Zhang, 2001).
Caspase-dependent apoptosis can occur via the intrinsic
apoptotic pathway, which involves depolarization of
mitochondria, controlled by changes in the Bcl-2 family
members, including BIM. Measurement of mitochondrial
outer membrane potential by JC-1 showed that I-BET151
treatment leads to depolarized mitochondria in Me1007,
Mel-RM, and Patient-3-pre cells (Figure 2c).
BIM is a proapoptotic member of the Bcl-2 family that
controls depolarization of mitochondria, leading to apoptosis
via caspase-dependent and -independent mechanisms. The
increase in BIM protein levels (Figure 2a) appeared to be due
to transcriptional upregulation as shown by the increase in
mRNA levels of BIM 6 hours after I-BET151 treatment
(Figure 2d). This was also evident in the melanocyte and
fibroblast lines.
To further investigate the role of BIM in I-BET151-induced
apoptosis, BIM was knocked down by siRNA in the sensitive
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Figure 1. I-BET151 inhibits the growth of melanoma cells in vitro and in vivo and induces cell death. (a) Me1007 melanoma cells were treated with 1, 10, 100mM
I-BET151, or vehicle control and cell growth was assessed over 72 hours using CellTiter Glo assay, with data normalized to a 0-h vehicle control. Error bars: SEM,
n¼ 8. (b) Average tumor volume of xenografted Patient-1-post cells in NOD/SCID mice treated with I-BET151 or vehicle control. (c) Cell death of matched pre/post
primary lines, human dermal fibroblasts (HDF), human melanocytes (HEM), and continuous melanoma cell lines after 48 hours of 10mM I-BET151 treatment was
quantified by annexin-V staining. (d) The cell cycle distribution was assessed using flow cytometry. Results are from at least three individual experiments.
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Me1007 cells and patient-3-pre cells. As shown in Figure 2e,
there was a substantial (480%) reduction in I-BET151-induced
apoptosis in the Me1007 cell line and a smaller reduction in
the Patient-3-pre line. Effective reduction of BIM protein was
confirmed by western blotting (Figure 2f). These results are
borne out by the photomicrographs shown in Supplementary
Figure S5A, showing less cell death following I-BET151
treatment in Me1007 cells with BIM ablated by siRNA.
I-BET151 induces cell cycle arrest by upregulation of p21
We examined the known cell cycle regulatory genes after
culture of the melanoma lines in 10mM I-BET151 for 48 hours.
As shown in Figure 3a and b, there was a consistent increase
in p21 and Cyclin D in the continuous lines and p21 in the
primary patient–derived lines. There was also an increase in
p27 and p53 in the latter lines. p53 increased in all the lines
except in Mel-RM and patient-3-post line. Bromodomain
target c-myc (Dawson et al., 2011; Puissant et al., 2013a)
was not detectably altered in our panel of melanoma cells.
To further investigate the role of p21 we knocked down
its expression by siRNA (Figure 3d). This diminished the G1
arrest induced by I-BET151 in the pretreatment cell lines from
patients 1 and 3 (Figure 3c), consistent with the dominant role
of this CDK inhibitor in regulating G1–S progression.
BRD2 proteins appear responsible for suppression of BIM,
whereas BRD4 suppresses CDKN1A (p21)
To determine which BRD proteins were involved in regulation
of BIM and p21, we knocked down the individual BRD
proteins using two separate siRNAs for each gene. As shown
in Figure 4a and b, BRD3 and BRD4 transcript levels were
effectively suppressed (60–80%) by the targeted siRNAs in the
Me1007 and Patient-3-pre cell lines. BRD2 message was also
knocked down by more than 50%, except by BRD2 siRNA#1
in the patient-3-pre treatment line.
As shown in Figure 4c and d, knockdown of BRD2 resulted
in increased expression of BIM (BCL2L11) in both Me1007
and Patient-3-pre cells, although the second BRD2 silencer
only caused a small, but statistically significant, increase in
BIM in Me1007 (Figure 4c). In contrast, knockdown of BRD4
by both silencing molecules resulted in a marked decrease in
the expression of the BIM gene in both melanoma lines.
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Ablation of BRD3 did not affect BIM mRNA levels. These
results were reflected at the protein level as determined by
western blot (Supplementary Figure S5B).
Knockdown of BRD proteins increases apoptosis and cell cycle
arrest
Although there was a clear difference in the effects of siRNA
for BRD2 and 3 compared with BRD4 on mRNA for BIM,
knockdown of each of the three genes increased apoptosis in
the patient-3-pre line, whereas only BRD2 siRNA increased
apoptosis in Me1007 (Figure 4c and d). The fact that BRD4
knockdown can cause apoptosis in patient-3-pre cells while
reducing BIM levels suggests that BRD4 normally suppresses
other mediators of apoptosis or upregulates antiapoptotic
proteins like Bcl-2, which was slightly reduced following
BRD4 ablation (Supplementary Figure S5B).
Both siRNAs against BRD4 produced G1 cell cycle arrest to
varying extent in both Me1007 and the line from patient 3
(Figure 4e and f), whereas only one each of the siRNA pairs
against BRD2 and BRD3 produced G1 arrest in the Me1007
line (Figure 4e).
I-BET151 upregulates proapoptotic and cell cycle arrest genes in
melanoma cells
We used gene expression microarrays to examine changes in
global gene expression 6 and 24 hours after exposure of the
cell lines from patient 1 and 3 to I-BET151. Using these data,
we first examined genes relating specifically to induction of
apoptosis. Figure 5 shows genes with expression that varied by
more than 50% following I-BET151 treatment. Genes are
grouped according to whether they were pro (red) or
antiapoptotic (green), according to GO gene ontology (GO
terms 0043066 or 0010942), or had been associated with
either role (blue bars). All four cell lines showed increased
gene expression of the proapoptotic proteins Noxa, Death-
associated protein kinase, RhoB, and Foxo3, 6 hours after
I-BET151 treatment. PMAIP1 (Noxa) is well described as a
BH3 protein induced by p53. STK17B (Death-associated
protein kinase ) was reported previously as a hypermethylated
gene in melanoma (Hoon et al., 2004) and to be involved in
UV-induced apoptosis (Kuwahara et al., 2006). RhoB is
considered to have a tumor suppressive role and to be
downregulated by the RAS/Akt pathway (Jiang et al., 2004).
The Foxo3 transcription factor upregulates BIM (Gillings et al.,
2009). There were no major differences between the
pretreatment line from patient 3 that underwent apoptosis
and the resistant line in this patient, which may suggest that
the induction of cell death is dependent on the balance
between pro- and antiapoptotic gene expression in each
line. Full data are given in Supplementary Table 1f–g.
We used the LimmaGP tool in GenePattern to identify genes
differentially expressed after I-BET151 treatment. Gene set
enrichment analysis identified a variety of downregulated
gene sets, including those relating to ribosomes, hormone
receptor binding, mitosis, and NF-kB, whereas there was a
mixture of upregulated gene sets (Supplementary Table 1c).
After 24 hours, the overwhelming number of downregulated
gene sets were related to mitosis and cell cycle
(Supplementary Table 1d). Downregulated genes within the
most significantly decreased gene set—Cell_Cycle_Process—
included cyclin A2, CDK4, CDK2, and aurora kinase
(Supplementary Table 1e).
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We also noted that many genes transcribing histone genes
were upregulated by I-BET151 treatment (Supplementary
Table 1). Histone gene transcription is normally tightly
regulated, and alterations in histone levels can perturb the
cell cycle and lead to apoptosis. These results require valida-
tion and further investigation.
DISCUSSION
The above studies have identified a number of potentially
important anticancer effects of I-BET151 against melanoma
cells that may be exploited in future preclinical studies. All
melanoma lines tested responded to I-BET151 with an altered
cell cycle or survival profile. This involved induction of G1
cell cycle arrest, mediated in part by the upregulation of p21
as shown in western blots and by inhibition of G1 arrest when
p21 was downregulated by siRNA. A subset of melanoma
cells also underwent caspase-dependent apoptosis in response
to I-BET151, and this was associated with the loss of
mitochondrial outer membrane potential. Apoptosis was
associated with upregulation of the BH3 proapoptotic BIM
protein in the majority of cell lines, and siRNA knockdown of
BIM confirmed it had a role in inducing apoptosis. A number
of other changes in pro- and antiapoptotic proteins were
detected in western blots, and further studies are needed to
give a more complete understanding of the changes respon-
sible for induction of apoptosis.
Successful development of treatments based on epigenetic
modifiers has largely been focused on hematologic malignan-
cies and with relatively nonspecific pan-HDAC inhibitors such
as vorinostat and panobinostat. Our preclinical studies have
also shown strong synergy between HDAC inhibitors and
selective BRAF inhibitors (Hersey et al., 2010; Lai et al.,
2012b), and recent reports suggest the benefit of targeting
epigenetic modulators in BRAFi-resistant melanoma
(Johannessen et al., 2013). The BET protein inhibitors like
I-BET151 and JQ1 are more restricted in their action and
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competitively inhibit BET protein binding to acetylated histo-
nes. They have shown selectivity for hematologic malignancies
driven by c-Myc and the rare NUT midline carcinoma. The
present study adds to information about nonhematologic
cancers that may be responsive to the BET protein inhibitors,
such as N-Myc-dependent neuroblastoma (Puissant et al.,
2013b), glioma (Cheng et al., 2013), lung carcinoma
(Lockwood et al., 2012), and melanoma (Segura et al.,
2013b). In the case of lung carcinoma, sensitivity to the BET
protein inhibitor appeared to be based on downregulation of
the oncogenic transcription factor FOSL1, which could be
reproduced by knockdown of BRD4 (Lockwood et al., 2012).
A previous study on human melanoma lines exposed to the
BET protein inhibitor MS417 did, however, find downregula-
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tion of c-Myc as well as ERK and SKP2 (Segura et al., 2013b).
In studies on gliomas, there was no association between
sensitivity to JQ1 and core signaling pathways such as Akt,
p53, or Rb pathways resulting from mutations in key pathway
proteins. This also appeared to be the case in the present study
on melanoma, but further analysis is needed to confirm this.
One of the most consistent effects of I-BET 151 was
upregulation of the BH3 proapoptotic Bcl-2 family protein
BIM, even though a range of other BH3 proteins such as Noxa
and Puma were unchanged or downregulated in the western
blot studies. The predominant isoforms of BIM (EL, L, and S)
can bind all antiapoptotic members of the Bcl-2 family and
have been shown to be potent inducers of apoptosis in
melanoma (Plotz et al., 2013; Berger et al., 2014). In our
studies, there did not appear to be differential expression of
the different BIM isoforms, with all being changed to the same
extent. The increase in BIM was seen at the mRNA level,
suggesting that upregulation was mediated transcriptionally
rather than by inhibition of degradation through the
proteasome that is known to be important in the biology of
BIM (Gillings et al., 2009; Faber et al., 2012). BIM can be
transcriptionally regulated by a number of transcription factors
such as E2F1, FOXO3a, CHOP-C during endoplasmic stress,
c-Myc, Rel-A, and c-Jun (reviewed in (Pinon et al. (2008)).
Phosphorylation of BIM by JNK was reported to result in its
release from microtubules, but this would not be expected to
change the overall protein levels (Gillings et al., 2009). As
reported elsewhere (Gallagher et al. submitted), I-BET151 is a
strong inhibitor of NF-kB in melanoma. It was also reported
that NF-kB was able to suppress BIM in response to a number
of stimuli (Banerjee et al., 2008; Wang et al., 2008; Busuttil
et al., 2010), but inhibition of NF-kB by BMS345541 (Yang
et al., 2006) in our studies did not upregulate BIM and did not
affect the induction of BIM by I-BET151 (data not shown). This
suggests that supression of NF-kB alone is not responsible for
the observed increase in BIM following I-BET151 treatment.
Gene expression array studies identified strong upregulation of
FOXO3 and downregulation of E2F2 by I-BET151, and
ongoing studies suggest these may be the main transcription
factors involved in regulation of BIM. There were neglible
changes in CHOP-C/EBP and c-Jun in our cells.
Although BIM was increased in all the melanoma lines
tested, apoptosis was cell line dependent. This may reflect
inhibition of BIM by oncogenic pathways such as the MAPK/
ERK kinase/extracellular signal–regulated kinase and phos-
phoinositide-3-kinase pathways, which phosphorylate and
inhibit the activity of BIM-EL (Gillings et al., 2009).
Similarly, variation in NF-kB activity may have contributed
to variation in sensitivity to apoptosis by reduction in XIAP and
BCL-XL levels, as reported elsewhere (Gallagher et al.
submitted). Induction of p53-dependent BH3 proteins Puma
and Noxa did not appear to be involved, as their protein levels
were unchanged or decreased by treatment with I-BET151,
even though mRNA transcripts of Noxa were strongly
upregulated at 6 hours in the gene expression arrays. We
presume that this is a result of rapid degradation of Noxa as
described by others (Brinkmann et al., 2013). The relatively
slow kinetics of apoptosis induction (48 hours) are consistent
with a model in which apoptosis mediated by BET inhibition
requires a number or cascade of transcriptional changes.
These changes could include both upregulation of BIM and
the disabling of pro-survival signaling provided by NF-kB or
other as-yet unidentified factors. The slow kinetics could also
suggest that the cell must progress through certain stages of the
cell cycle to undergo apoptosis; however, reduction of G1
arrest by ablating p21 did not increase cell death, providing
little support for this hypothesis.
Our analysis of the mechanisms underlying cell cycle arrest
was largely consistent with previous studies showing that this
appeared to result from upregulation of p21 (Cheng et al.,
2013) and in some lines p27. In melanoma lines with
upregulation of both p21 and p27, knockdown of p21
reduced G1 arrest, suggesting it was the main cell cycle
inhibitor. The basis for upregulation of p21 is, however, not
clear. Although p53 was upregulated by I-BET151,
knockdown of p53 did not alter G1 arrest (data not shown).
This, together with the studies on the p53-null Me4405,
suggests that p53 was not a key transcription factor in cell
cycle arrest mediated by I-BET151. C-Myc involvement in the
cell cycle arrest appeared unlikely, in that there was no or
minimal downregulation of c-Myc by I-BET151 at the protein
or mRNA level.
Knockdown studies of individual BRD proteins suggested
that BIM was regulated principally by BRD2. Inexplicably, the
knockdown of BRD4 was associated with reduced levels of
BIM in both cell lines even though apoptosis was increased in
both lines. We interpret these findings as indicating that BRD2
may normally suppress BIM, whereas BRD4 is part of com-
plexes upregulating BIM. It is possible that, following the
ablation of BRD4, the suppression by BRD2 is unopposed,
resulting in lower levels of BIM, whereas I-BET151 treatment
also relieves BRD2 suppression and, possibly, activates BIM
transcription via other indirect methods. Further studies are
needed to see whether a possible feedback mechanism by
BRD2 may be involved. As reported elsewhere, BRD2 also
appeared to be the main protein involved in regulation of NF-
kB (Gallagher et al. submitted). In contrast, BRD4 appeared to
be the major protein involved in cell cycle regulation in
melanoma as shown by the siRNA studies, in agreement with
reports by others (Segura et al., 2013a).
These initial studies show that induction of apoptosis may
be an important additional mechanism that can be added to
effects of BET inhibitors on cell cycle and NF-kB in treatment
of cancer. Further studies are needed to define which
transcription factors are involved in the upregulation of Bim.
BRD2 and BRD4 appeared to have opposing effects on
regulation of BIM, and the basis for this requires further study.
It also raises questions as to whether selective inhibitors
against BRD2 may have merit. In addition, should the marked
heterogeneity in apoptotic responses between the cell lines
translate to heterogeneity of clinical responses, identification
of biomarkers may be critical in patient selection. Interest-
ingly, I-BET151 reduced the growth of Patient-1-post (vemur-
afenib resistant) cells more strongly in vivo than in vitro. This
might be explained by the previously mentioned effects of
I-BET151 on NF-kB activity and cytokine production, as
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autocrine signaling can be more important to support growth
in vivo than in culture.
Our results highlight the potential of using BET inhibitors in
combination with other drugs, with BET inhibition priming
cells to undergo apoptosis via increased levels of BIM and
decreased BCL-2, BCL-XL, and XIAP. Taken together, the
present results provide evidence that I-BET151 has several
potential effects against melanoma cells that are independent
of known mutational and signal pathway activation and justify
further investigation for their use in treatment for melanoma.
MATERIALS AND METHODS
Cell lines
Human melanoma cell lines Mel-RMU, Sk-Mel-28, Mel-RM, Mel-JD,
and Me1007 have been described previously (Zhang et al., 1999).
Cells were cultured in Dulbecco’s modified Eagle’s medium
containing 10% fetal calf serum (AusGeneX, Brisbane, Australia). In
addition, primary melanoma cell cultures were established, as
described previously (Nguyen et al., 2001), from two patients
entered into the Roche ‘‘BRIM2’’ phase II study of vemurafenib in
patients who had failed previous treatment. The patient lines were
established before treatment and during relapse from treatment with
vemurafenib, labeled ‘‘pre’’ and ‘‘post’’, respectively, as described
elsewhere (Lai et al., 2012a). These studies were approved by the
Hunter and New England Research Ethics Committee.
Chemicals and transfections
I-BET151 was supplied by GlaxoSmithKline (Brentford, UK). The
caspases were inhibited by the addition of 10mM Q-VD-OPH (SM
Biochemicals, Anaheim, CA) to medium 3 hours before I-BET151
treatment. For gene knockdown studies, siRNA was purchased from
QIAGEN (Limburg, The Netherlands) (non-silencing control
(1027281), BIM (SI02655359; SI04951968), p21 (SI00604898;
SI00299810), BRD2 (SI04256966, SI05015150), and BRD3
(SI03125150, SI04140178)) or from Shanghai Gene Pharma
(BRD4 (5’-GGAGAUGACAUAGUCUUAATT-3’, 5’-GCACAAUCAA
GUCUAAACUTT-3’)) and transfected with Lipofectamine RNAiMax
(Invitrogen) into cells 24 hours before I-BET151 treatment.
Quantitative reverse transcriptase–PCR
RNA was extracted from cell lines using the RNeasy Plus mini prep
kit (QIAGEN), quantitated using a Nanodrop (Thermo Scientific,
Wilmington, DE), and 1mg RNA reverse transcribed with Super-
ScriptIII (Invitrogen, Carlsbad, CA). cDNA was amplified on AB7900
(Applied Biosystems, Carlsbad, CA) using Universal PCR Master Mix
and Taqman probes (Applied Biosystems) specific for BIM
(Hs00708019_s1), p21 (Hs00355782_m1), BRD2 (Hs01121986_g1),
BRD3 (Hs00201284_m1), and BRD4 (Hs04188087_m1), and nor-
malized to levels of 18S (Hs99999901_s1).
Analysis of cell viability, cell death, cell cycle, and mitochondrial
membrane potential
Cell growth assays were performed using CellTiter-Glo (Promega,
Madison, WI) as described by the manufacturer. Apoptotic cells were
quantified using Annexin-V/propidium iodide staining as described by
the manufacturer (Becton Dickinson, Franklin Lakes, NJ), and mea-
sured using a Becton Dickinson FACSCalibur flow cytometer. Cell
cycle was analyzed by measuring propidium iodide-stained cells
using a FACSCalibur flow cytometer and cell cycle fitted to viable
cells using ModFit LT software (Verity Software House). For BrdU
experiments, cells were pulsed with 10mM BrdU for 40 minutes and
processed using the BD Pharmingen BrdU Flow Kit (Cat No. 552598).
Changes in mitochondrial membrane potential (DCm) were studied
by staining the cells with the cationic dye JC-1, according to the
manufacturer’s instructions (Molecular Probes, Eugene, OR).
Western blotting
Western blot analysis was carried out as described previously (Irvine
et al., 2010). Antibodies used were Bak (G-23, Santa Cruz, Dallas,
TX); Bax (Cell Signaling, Danvers, MA); Bcl-2 (C-2, Santa Cruz); Bcl-
xL (H-5, Santa Cruz); Beta Actin (AC-74, Sigma); Bid (Cell Signaling);
Bik (C33-1, BD Biosciences); BIM (C34C5, Cell Signaling); BMF
(G81, Cell Signaling); cleaved caspase 3 (Cell Signaling); c-Myc
(9E10, Santa Cruz); cyclin D1 (G124-326 BD Biosciences); Mcl-1 (22/
Mcl-1, BD); Noxa (sc-26917, Santa Cruz); p21 (Millipore, Billerica,
MA); p27 (C-19, Santa Cruz); p53 (DO-1, Santa Cruz); Puma (Cell
Signaling); and XIAP (20/hILP/X, BD).
In vivo experiments
All animal experiments were performed in accordance with the
Australian Code of Practice for the Care and Use of Animals for
Scientific Purposes, 7th Edition, and with approval from the Peter
MacCallum Cancer Centre Animal Experimentation Ethics Commit-
tee. Female NOD/SCID mice were injected subcutaneously into the
flank with 4 106 Patient-1-post cells in 50% Matrigel. Once tumors
had grown to approximately 130 mm2, mice were randomized into
two groups of nine mice each and each group was administered
either 25 mg kg 1 I-BET151 or 1% methylcellulose vehicle daily by
oral gavage on days 1–7 and 20 mg kg 1 on days 10–15.
Transcriptome analysis
Total RNA was extracted in duplicate from 75 cm2 culture flasks of
both ‘‘pre’’ and ‘‘post’’ cell lines from Patient 1 and Patient 3 at 6 and
24 hours after cells had been treated with 10mM I-BET151 or DMSO
control. The RNA was isolated using TRIZOL and purified with an
RNeasy purification kit (Qiagen) with DNAse I digestion on the
column, and the RNA quality was verified using the Agilent 2100
Bioanalyser (Agilent Technologies, Palo Alto, CA). Gene expression
analysis was performed using the HumanHT-12 v4 Expression
BeadChip (Illumina, San Diego, CA) and BeadStation system from
Illumina. Quality control was performed on all chips using Geno-
meStudio (Illumina). Data were log2 transformed and quantile normal-
ized following filtering out of unexpressed probe sets. Probe sets were
collapsed into single genes, and paired LimmaGP analysis was
performed on all cell lines, comparing DMSO- vs. I-BET151-treated
cells at either 6- or 24-hour treatment lengths. These results were used
to perform Gene Set Enrichment Analysis, which identifies whether
predetermined sets of genes tend to be upregulated or downregulated,
in GenePattern using the Broad Institute database MSigDB.
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